2023-01-05 19:46:01

On the first day of the medical insurance negotiat

According to the List of Medicines that have passed the preliminary form examination in 2022 for the adjustment of the national basic medical insurance, work-related injury insurance and maternity insurance drug list previously released by the State Health Insurance Bureau, a total of 343 drugs have officially passed the form examination, with a proportion of 70%, including 198 kinds of western medicines and Chinese patent medicines outside the list and 145 kinds of western medicines and Chinese patent medicines within the list.

The drugs in the medical insurance negotiation in 2022 involve clinical drugs such as tumor, rare disease and COVID-19 infection treatment, including multiple products of Pfizer, Hengrui Pharmaceutical, Baekje Shenzhou and other enterprises. Among them, two COVID-19 oral drugs Azivudine and Paxlovid, "one million one shot" CAR-T products Ruijiorensei injection, Hengrui Pharmaceuticals Karelizumab, Baekje Shenzhou Tirelizumab, Xinda Bio Sindilimab injection, Junshi Bio Terepril Monoclonal Antibody PD-1/PD-L1 Monoclonal anti tumor drug popular varieties, as well as a number of high-value rare disease drugs all participated in the negotiation.